NEW YORK, July 1, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy market, today announced that Company management will give a presentation at the 8th annual JMP Securities Healthcare Conference on Tuesday, July 9, at 12 PM EDT at The St. Regis New York.
NeoStem also announced the launch of a redesigned Company website at www.neostem.com, featuring a focus on the company's three primary platform technologies, Amorcyte (cell therapy for the treatment of cardiovascular disease), Athelos (T-cell therapy for autoimmune and inflammatory conditions), and VSEL™ Technology (very small embryonic-like stem cells offering the potential for true cellular regeneration for a variety of conditions). The website provides downloadable one page fact sheets on each of these platforms, as well as on NeoStem's contract and development manufacturing organization, Progenitor Cell Therapy (PCT). The website also provides links to abstracts for peer-reviewed literature in support of these technology areas, describing the data upon which these platforms are based. Sections of the website on NeoStem's technology platforms can be found at www.amorcyte.com, www.athelos.com, and www.vseltechnology.com.
About NeoStem, Inc.
NeoStem, Inc. ("NeoStem" or the "Company") is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation.
For more information, please visit: www.neostem.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's research and development and clinical evaluation efforts for cellular therapies, including with respect to AMR-001, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the Company's ability to successfully grow its contract development and manufacturing business. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 11, 2013 and in the Company's periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
CONTACT: NeoStem Dr. Robin L. Smith Chairman and CEO Phone: +1-212-584-4174 Email: email@example.com